

News LETTER



Newsletter - Vol 9, No 4, December 2007 • International Society of Oncology Pharmacy Practitioners

Message from Acting President

ISOPP Members, Committees and Secretariat have had a busy productive few months from my perspective.

As an ISOPP Member, thank you for considering putting your name forward in our nomination call for election to the ISOPP Secretariat. A strong and vibrant Society such as ISOPP needs each of us to contribute our time and talents so I was delighted at the willingness of our members to stand for these important positions. Thank you also to each ISOPP member who has already renewed their membership for 2008. The addition of your financial commitment to ISOPP on your individual member profile was added to the User Preferences section of the website in 2007 so if you cannot recall if you have paid for 2008 yet please

check this section. This is also a record of how much you paid and enables you to keep track of your selected salary band.

Did you file a letter of Intent for a possible Research Grant? Have you tidied up your Abstract and submitted it for the upcoming Joint ISOPP XI/HOPA symposium? Registration for the upcoming symposium in June 08 will open soon. Have you put your name down on the HOPA website <http://www.hoparx.org/registrationGrid.aspx> to be notified when registration opens? If not, do it now! Thank you everyone for seeking out local sponsorship to attend this joint symposium between ISOPP and HOPA. Don't forget to nominate for awards and travel grants through ISOPP. These have recently been posted on the our ISOPP website. Many tasks to undertake but such opportunities for members.

Your ISOPP Committees have also been very active. Your Standards Committee celebrates the publication of the First Standard in the sponsored September supplement of JOPP - awesome. Your Research Committee is actively reviewing the next research grant competition as well as calling for abstracts to be presented in Anaheim. Your Publication Committee has been busy upgrading and contributing to various sections of the website as well as creating a jam packed newsletter for us. Your Education Committee was pleasantly overwhelmed with volunteers for the scientific committee and is now intensely focused on the planning for the upcoming Joint symposium in June. Your Membership and Finance committee continues to focus on the financial health of ISOPP and have updated the

awards/grants as well as reconfirming their membership in readiness for the review required. Your Committee reviewing the Constitution and Rules of ISOPP has developed a timeline to ensure the membership can have input and ultimately come to agreement on updates to our structure at our General Assembly in Anaheim. The Committee structure continues to work well for our Society to move us forward on many fronts.

The ISOPP Secretariat, in collaboration with many of the committees, has been involved in many of the above pursuits. We have developed a sponsorship framework which can be found on our website if you are interested in sponsoring ISOPP or are approached for how someone could assist ISOPP. Our financial health and house have been reviewed and put into order as we had decided in March in Vancouver at the Secretariat meeting. Since August there has been a joint overseeing group meeting between ISOPP and HOPA to ensure we have a superb meeting in June. We received many expressions of

Continued Page 2



CONTENTS

1. Message from Acting-President
Carole Chambers
2. Membership and Finance
Committee News
3. BOPP/Gerpac Combined Meeting
4. Australasian ISOPP Symposium
5. BOPA meeting
6. Invitation from the Standards
Committee
7. Second Call for Abstracts
ISOPP/HOPA
8. Request for Peer Reviewers

interest for hosting the 2010 ISOPP so now are in the process of reviewing this to ensure planning can start both at the membership level to attend and at the organizing committee level for the next meeting. Our nomination committee is now finished and again let me say how impressed and gratified I was that our membership is willing to come forward and share their time and talents with ISOPP. Your Secretariat strongly supports investigating the option for electronic voting so that work is underway.

I had not realized how many conferences happened over the months of September, October and November until we tried to get the ISOPP/HOPA first announcement to as many members as possible and were overwhelmed at the number of opportunities to interact with members. ISOPP members are also members of their local and national groups which is a strength - we are 'joiners' and our contributions add value to many aspects of oncology pharmacy. I am reminded of the catch phrase: Think Globally, Act Locally. My wish for each of you is that the holiday season is a time of relaxation, reflection and recharging. I look forward to seeing you in Anaheim a few short months.

Sincerely
Carole R Chambers
Acting President

Comment on DRAFT revised ISOPP Constitution

Within the next few weeks, a copy of a DRAFT revised ISOPP Constitution will be posted on the ISOPP Website. Members will notified, via email, when this is available. If you prefer to receive a copy of the DRAFT via regular postal mail, please contact: Helen McKinnon
helenm@internet.co.nz or Helen McKinnon CMC International 52 Hall Road RD2, Hamilton 3282, New Zealand

Membership and Finance Committee News

A review of the membership database at the beginning of November 2007 shows that ISOPP has 443 paid and 88 new/rejoining members. These members come from 44 different countries. Germany has the largest number of members (165), followed by Australia (64) and the USA (36). One positive finding is that we have many members from Asia (total 56), after our the meeting in Kuala Lumpur in 2006. One of the tasks of the Membership and Finance Committee is overseeing the Grants and Awards Program of the society and they are described below..

The 2008 ISOPP Grants and Awards are as follows:

ISOPP Travel Grants

offer ISOPP members from developing countries or with financial hardship the opportunity to attend ISOPP XI in Anaheim, California in the USA, 18-21 June, 2008. The aim is to expand the grant recipient's current knowledge through attending the educational sessions and events and to enable them to share that knowledge with colleagues in their home countries/regions. The award is 500 Euro each and designed to cover some (not all) of the expenses incurred to attend the meeting in Anaheim. Application deadline 29 February, 2008.

The ISOPP Fellowship Program

is intended to recognize excellence in oncology pharmacy practice and grants recognition to and promotes global awareness of pharmacists who have distinguished themselves in oncology pharmacy practice. Fellowship is awarded to individuals who have

demonstrated a continued high level of excellence in oncology pharmacy practice, research, or management, and who have made a sustained contribution to ISOPP. At ISOPP IX in Turin (2004), the first 3 ISOPP Fellowships were awarded to Jill Davis, Peter Gilbar, and Jude Lees (all from Australia) and at ISOPP X in KL a Fellowship was awarded to Barry Goldspiel. Fellowships could be awarded again in 2008. Many of you are worthy of this recognition, so why not apply? Application deadline 31 March, 2008.

The Helen McKinnon Award

recognizes an ISOPP member who has made a significant contribution to ISOPP or a sustained contribution to oncology pharmacy practice. Nominees must have been an ISOPP member for at least 5 years. Members are encouraged to write a letter outlining the achievements of their nominee to the ISOPP President. Application deadline 31 March, 2008.

ISOPP Achievement Awards

recognize ISOPP members who have made a significant contribution or provided leadership to developing or supporting an innovative technical or clinical oncology pharmacy service. Application deadline 31 March, 2008.

Grants and Awards Program Application Forms and Selection Criteria are available on our Web site, www.isopp.org (Grants and Awards section).

Thomas Garms
Chair, Membership and Finance Committee

'Evidence based oncology in the website, tip and tricks.

It is now possible to search the news section on the website for specific information by using the search function. If are you interested in Cochrane Reviews it is possible to search for these by going into the Members Area and clicking on 'news archive'. Then you have to fill the blank field with the keyword 'cochrane' and click 'search'. In this way you will retrieve all the news we have published about Cochrane reviews. In the same way using the keywords FDA or EMEA, you will see all the news about decisions of those Agencies. I also remind you that in the Educational Area of the website it is possible to see all the most important recent news about therapy, toxicities and supportive care. We would like to receive your feedback and ideas about what would you like to see in the website and what you consider most useful so that we can improve your evidence based clinical practice.

Many thanks - Felice (Publications Committee Chair)

BOPP-GERPAC - a successful initiative

Mol - October, 3 - 5 was the place to be for Hospital Pharmacists of Belgium and France who are working in the oncology/haematology field.

For BOPP (Belgian Oncology Pharmacy Practitioners) it was the first congress to be organised since the inaugural meeting of November 2005. GERPAC (Groupe d' Evaluation et de Recherche sur la Protection en Atmosphère Controlée - France) was celebrating their 10th congress and 5th meeting held outside France.

More than 400 registered participants enjoyed a mixed program of plenary lectures, workshops, oral presentations of clinical and practical aspects of the use, treatments, handling and safety of cytotoxic drugs in hospitals.

An exhibition hall with 42 booths of pharmaceutical companies hosted the coffee breaks.

The congress started with a session of Clinical Oncology Pharmacy where colleagues from Belgium (Tiene Bauters - UZ Gent) and Canada (Carole Chambers - Alberta Cancer Board, Calgary) shared their experiences of setting up and implementing such a service. Some examples of intervention in the therapy and the degree of acceptance by the physicians was presented. Finally the results of the questionnaire about the training and education of Hospital Pharmacists in Belgium was discussed by Greet Engelmann - AZ St Maarten, Duffel and France Duvivier, CHPTL Verviers. A consensus was seen in the expectations towards the universities (supplying basic education) and BOPP (supplying postgraduate and continuous education). In the afternoon lectures about chemical contamination with cytotoxic drugs in hospital pharmacies were presented from Italy (Roberta Turci - Laboratory for environmental and toxicological testing Pavia), Sweden (Ole Nygran - Umea university), The Netherlands (Paul Sessink, - exposure control, Nijmegen), Germany (Rudolf Shierl - Institute for occupational and environmental medicine, Munich), Canada (Jean-Francois Bussiè res - CHU Sainte Justine, Montreal), UK (Richard Bateman - St Thomas hospital, London) and France (Sylvie Crauste-Manciet -



from left to right: Johan Vandenbroucke - Belgium, Carole Chambers - Canada, Sylvie Crauste-Manciet President of Gerpac and ISOPP Standard Committee member, Graham Sewell, former president of ISOPP, Jean Vigneron Nancy France and chief editor of the stability data DVD Stabilis, Jean-Daniel Hecq, Namur - Belgium and president of the Belgian association of Hospital Pharmacists

Descartes university, Paris). A debate following these short introductions pushed the audience into detailed evaluation of procedures, analytical methods and improvements required to decision tools. Centralisation of cytotoxic preparations, strict procedures, intensive training in the use of special devices such as “closed systems” had a major impact in reducing contamination levels. Questions as “how low should/must we go in detection limits?”, “what is the best sampling method?” remained unanswered. A general call towards pharmaceutical companies was heard to deliver contamination free vials and analytical reports of external wipe samples.

The second day started with “radiopharmaceutical preparation in Hospitals”. Bernard Van Gansbeke - ULB Erasme, Brussels, highlighted the similarities in safe handling with cytotoxic drugs and the particularities of the radiation protection. Advantage over the cytotoxic drug is the presence of permanent monitoring and maximum acceptable levels of radiation. Johan Vandenbroucke - UZ Gent explained the history, background, technique and pitfalls of “Hyperthermic intraperitoneal

preoperative chemotherapy” and the practical experience over 130 patients treated with this procedure. The outcome is promising especially for people suffering from pseudomyxoma peritonea. The presentation “the choice criteria of gloves” by Pierre Wallemacq – St Luc Brussels, tried to explain why the existing standards for glove testing might not be the right choice. Difference between static and dynamic testing and test results were shown.

After the break 4 different workshops were offered in the following topics: “Quality audit for anticancer drug preparation”, “Activity level measurement”, “dose banding - standardization” and “Other toxic drug to prepare in Pharmacy”.

The “Quality audit” workshop based their activity on an audit tool with > 260 comprehensive questions, developed by the BOPP and based on the ISOPP standard. A general enthusiasm about this tool for self evaluation was expressed by the requests of different organisations and country liaisons to get a copy of it. It was decided that it would be the subject of an article because of its general importance for the hospital pharmacy world.

Continued next page

BOPP-GERPAC continued

The “activity level” workshop covered a variety of parameters needed to help the hospital pharmacist produce documents to be used for both management and quality purposes. Other measurements can assist in creating a more economical or efficient use of staff and resources.

The “dose banding” workshop discussed which products could benefit from dose banding. Fluorouracil is a well known candidate but experiences in the UK suggested that the dose banding of $\pm 5\%$ could be increased to $\pm 10\%$ with equal outcome thus reducing preparation times/costs. Carboplatin as a possible candidate was also discussed based on experience in the UK.

The “other hazardous drugs” group commenced with an introduction from a physician who expressed concerns from an industrial medicine angle. Prevention and monitoring of possible exposure were the key words. After the introduction, the group tried to set up an overview of drugs that should be handled as potentially hazardous and relied on the IARC and NIOSH lists. Special attention was given to the new generation of chemotherapy with an increasing importance of the monoclonal antibodies (Mabs) and the small molecules (Nibs). Recent publications suggest that some of these drugs could produce organ toxicities and severe side effects that were not seen in the introduction phase of these drugs and that prudence in handling is essential.

The rest of the day was devoted to giving young colleagues an opportunity to present their work in short oral presentations. Many of them presented for the first time in their professional life and this opportunity was taken by 12 enthusiastic pharmacists with great acceptance from the audience. The final day started with an entire morning spent on “Good Manufacturing Practices” and the question was can we get a consensus and what that would be.

5 speakers presented different approaches to the GMP concept. V’ian Fentom-May - Cardiff, UK, presented the PIC/S (Pharmaceutical Inspection



from left to right: V’ian Fentom-May Cardiff - UK, Carole Chambers - Canada, Jean-Francois Bussieres, Montreal - Canada, Johan Vandenbroucke - Belgium, Denis Brossard, Paris - France, Frashid Sadeghipour, Geneve - Switzerland

Cooperation Scheme) which is an audit tool for the pharmaceutical inspection services of Europe when they come to visit the pharmacy on compliance to GMP rules. Based on the industrial GMP guidelines, it is adapted to hospital level. For the moment it is only a draft but foreseen is an official publication in 2008.

The next 2 speakers presented national GMP guidelines from Switzerland (Farshid Sadeghipour, HUG Geneva) and France (Denis Brossard - Descartes university, Paris) and the impact of it on daily practice, installation and equipment.

The world standard on safe handling of cytotoxics published by ISOPP was the subject of Carole Chambers, acting President of ISOPP. This standard combines safe handling issues, GMP requirements, management and clinical pharmacy tools and was written and commented on by pharmacists from all over the world. The importance of having international acceptance of this important document was stressed. The last speaker (Jean-Francois Bussières, Montreal) of the session brought the USA/ Canada view on GMP and the impact of the USP 797 publication on Pharmacy life. The practical approach of dividing sterile preparations into different risk levels and the consequent preparation requirements and shelf life according to the risk level met with audience

approval.

After lunch a new booklet was presented and distributed to the attendees. “Recommendations for the use of medical devices in the preparation and administration of drugs with potential risk for staff and environment”. This work was prepared by the GERPAC and EUROPHARMAT, an organisation of pharmaceutical companies and pharmacists involved in medical devices. This initiative was rewarded with acclamation from the audience. Presentations from this meeting will be on the GERPAC website at: www.gerpac.org/fr/index.htm. The next GERPAC congress is in October 2008 in France. BOPP is already planning a follow-up meeting in January 2008 and a symposium for the oncology pharmacists of Belgium in November 2008.

The congress was successful, the attendees scored on the evaluation forms good to excellent, the industrial sponsors were happy with the many contacts they made and all said ‘a job well done’ and ‘looking forward to the next one’.

Johan Vandenbroucke, Pharm D.
Senior Pharmacist Production
University Hospital Gent
Central Pharmacy

Ed. I certainly look forward to the publication of the BOPP quality audit tool with the self-evaluation test based on the ISOPP standard.

ISOPP 5th Australasian Regional Symposium



Johan Vandenbroucke and Harbans Dhillon

ISOPP 5th Australasian Regional Symposium

Alexandre Chan, Pharm.D. Singapore

ISOPP held its fifth Australasian Regional Symposium in Brisbane, Australia from September 28th to 30th, 2007. Over 100 participants from Thailand, Malaysia, Singapore, Hong Kong, Taiwan, New Zealand as well as Australia attended this wonderful meeting.

The programme kicked off on Friday afternoon with keynote sessions conducted by Dr. Johan Vandenbroucke from Belgium and Christine Carrington from Australia. Both speakers focused on safe dispensing of chemotherapy within today's context. Dr. Vandenbroucke discussed the potential chemotherapy errors that can occur in the age of electronic prescribing, while Christine discussed the



Brisbane

potential safety issues with oral chemotherapy agents. Following the keynote sessions were informative, clinical update sessions on breast, lung and colorectal cancer. After all the educational sessions, the organizing committee held a cocktail party and it has provided a great opportunity for our regional colleagues to network. The Saturday scientific programme included a variety of topics of interest to pharmacists. To kick off, there were advances and updates on ovarian cancer and multiple myeloma, following by multiple concurrent breakout sessions conducted by various speakers. Numerous interesting topics were presented during the breakout sessions, ranging from clinical topics such as management of EGFR inhibitor skin toxicities and technical topics such as safe handling updates. Before the end of the day, there was a poster viewing session showcasing ten posters from different institutions.

On Sunday, there were more update sessions on bladder cancer and renal cell carcinoma therapeutics, followed by a session on pearls of wisdoms. The meeting officially closed after the ISOPP trivia quiz.

In conclusion, I have enjoyed my first ISOPP meeting, as well as my very first visit to Brisbane. I learned a lot from the meeting and I am very glad that I had the opportunity to network with other oncology pharmacists in the region. I realize that we all are facing similar issues in our daily practice, and every one of us are striving hard everyday to work towards the same goal, that is, to optimize the treatment outcome of the patients that we take care of.

The next ISOPP meeting is a joined meeting with HOPA, and it will be held in June 2008 in Anaheim, USA. I hope to see each of you at this meeting!

Fellowship Award

Do you think you are eligible for an ISOPP Fellowship Award? Complete the criteria and submit in time to receive your Fellowship at the ISOPP IX / HOPA IV meeting

ISOPP Travel Award

If you would like to attend the combined ISOPP XI/ HOPA meeting but are unable to afford the entire cost of attendance, you might be eligible for an ISOPP Travel award. See the website (isopp.org) for further details.



Olive Lai and Alex Chan

GLIMPSE from BOPP-GERPAC 2007

Tiene Bauters and Nathalie Beck, Belgium

The 1st Belgian Oncology Pharmacy Practitioners' (BOPP) Conference and the 10th Conference of the Groupe d'Evaluation et de Recherche sur la Protection en Atmosphère Controlée (GERPAC) were held together in Mol, Belgium, October 3-5, 2007.

As BOPP was launched very recently, they took the opportunity to collaborate with the French GERPAC meeting for the organization of their first conference. More than 400 participants from all over the world joined this very interesting meeting.

For those unfamiliar with BOPP, it is a non-profit professional organization of pharmacists, educators and researchers who want to specialize in oncology pharmacy. BOPP exists to advance human health and quality of life by helping pharmacists expand the frontiers of their practice and research. Its core purpose is to provide leadership, education, advocacy, and other resources that enable pharmacists to achieve excellence in clinical practice and research, advancing pharmacotherapy through support and promotion of research, training, and educational programs. This is achieved through 3 working groups: Cytotoxics, Audit and Research and Education.

The afternoon plenary session of the first day was about "Clinical Oncology Pharmacy". This session opened with a presentation 'Implementing clinical oncology pharmacy services' by the president of ISOPP, Carole Chambers, followed by presentations about 'Clinical Pharmacy in pediatric oncology' (Tiene Bauters) and 'Pharmacy personnel education: reality and expectations' (Greet Engelmann and France Duvivier).

This was followed by a debate about chemical contamination with cytotoxic drugs in hospital pharmacies which described the collective protection equipments and key results on environmental and biological monitoring in hospital pharmacies


The second plenary session was a review of the 'Use of radiopharmaceuticals' (Bernard Van Gansbeke), 'Hyperthermic Intraperitoneal Peroperative Chemotherapy' (Johan Vandenbroucke) and 'Choice criteria about gloves' (Pierre Wallemacq). This was followed by four concurrent workshops including 'Quality audit for anticancer drugs preparation, activity level measurement for anticancer drugs preparation, dose-banding cytotoxic drugs standardization and other toxic drugs than cytotoxics to be prepared in centralized units'. After this long session, everybody joined the Gala Dinner at the Tropical Swimming Pool.

The last day opened with a debate about Good Manufacturing Practices for antineoplastic drugs with presentations from V'Ian Fenton-May (UK), Farshid Sadeghipour (Switzerland), Denis Brossard (France), Carole Chambers (Canada) and Jean-Francois Bussi eres (Canada).

Due to the success of this meeting, BOPP plans to organize future symposia.

BOPA/ISOPP REPORT

Matthew Small
Norfolk and Norwich University Hospital
NHS Trust, UK.



The Tenth anniversary annual symposium of the British Oncology Pharmacy Association (BOPA) took place at the Scottish Exhibition and Conference Centre on 12 - 14 October 2007.

This was the second time in two years that the annual symposium has been held at this venue, part of which is the well-known armadillo like structure of the concert hall which adjoins the conference centre and is impressively situated in a re-developed area along the banks of the river Clyde. On a sunny day, and with a new suspension bridge in the background, you could almost imagine a scene reminiscent of that in Sydney Harbour. However, on an overcast October weekend in Glasgow, it at least served as a more than suitable site for an oncology pharmacy conference.

Unfortunately a late flight meant that I missed the first series of sponsored lectures, so the conference began for me with a session of pharmacogenomics by Professor Jim Cassidy of the Beatson Oncology Centre in Glasgow where a number of important issues were highlighted. For instance, identifying tumour sub-types that are not likely to respond to standard treatment is a key research area. However it would not necessarily be in the interests of pharmaceutical companies to develop this research as it may potentially reduce the number of patients who are eligible to receive their particular agent. Nevertheless the push to prove the cost-effectiveness of new high-cost drugs may represent a turning point as removing potential non-responders from clinical trials will help to improve response rates. The identification of non-responders also represents a new dilemma for clinicians who may not be able to offer a patient a standard treatment, or any treatment at all if no alternative option is available. Next I attended a joint presentation from Keith Ridge and Bill Scott, Chief Pharmaceutical Officers for England and


BOPA/ISOPP REPORT *continued*

Scotland respectively. Both speakers encouraged oncology pharmacists to get out of their comfort zones and become what was termed 'confident carers'. This could be achieved in a number of ways including promoting the safe use of oral chemotherapy, developing standards of delivery for chemotherapy given in the community and encouraging practice research in areas related to oncology pharmacy practice. Working closely with the private sector and community pharmacy in promoting cancer prevention was a recurring theme. Personally speaking I think this is laudable and highly important but I couldn't help thinking that promoting prevention may be a step too far out of my own 'comfort zone'.

The first day closed with presentations from the selected best posters and an opportunity to view the rest of the excellent posters displayed during a drinks reception in the exhibition hall. Delegates were then given a free evening to explore Glasgow and if anyone ever finds themselves in desperate need of a good Chinese meal while visiting the city I can highly recommend the restaurant a party of us ended up in. The wine was also of a very high standard so my memory of how to get there may not be so good.

The Saturday program was divided into streams and with the increasing use of concomitant chemotherapy, and to brush-up on my knowledge of radiotherapy, I felt the chemo-radiation stream would be the most informative to attend. The first two sessions were particularly good for learning about the different ways that radiotherapy works, the theory behind fractionation and tumour re-population following radiotherapy, planning radiotherapy courses and the acute and late damage inflicted on normal tissue.

The next session concentrated on concurrent chemo-radiation. This was very informative in explaining why chemo-radiation is given and the theory



behind radiosensitisation was especially interesting and something I would like to look into further to truly understand. Finally there was a session delivered by a local radiopharmacist on the use of radiopharmaceuticals in cancer. Although on one hand it was slightly disappointing to reflect that the use of targeted therapeutic radiopharmaceuticals in cancer treatment has not progressed as far as may have been hoped, on the other hand the use of PET imaging is proving to be a very useful tool both for assessing response to treatment and enabling radiotherapy to be planned with greater precision.

The day's plenary session was entitled 'Oncology Pharmacy Practitioners - into the future'. This involved a number of speakers debating how best to formally accredit oncology pharmacists along the journey from a junior practitioner through to advanced practitioner and ultimately consultant oncology pharmacist. The overall consensus was that as a speciality we need to be proactive in setting up a system of accreditation and a vote was taken at the subsequent annual general meeting to agree how best this could be achieved. The majority view favoured the setting up of a joint venture between BOPA and the College of Pharmacy Practice. To have a nationally recognised structured system for accrediting oncology pharmacists should represent a major advancement on the current 'system' where a

practitioner's value is judged loosely on experience and their individual employers grading structure.

The final lecture of the day was a presentation from Peter Boyle, Director of the International Agency for Research in Cancer on the 'Globalisation of Cancer'. This was full of interesting statistics, the most significant being the increased number of people smoking tobacco products in China that peaked during the 1990's and will translate into a large rise in global lung cancer rates over the next 10-20 years. Figures also demonstrate that for each unit of alcohol a woman consumes on average per day her individual risk having of breast cancer is increased by seven percent. Although this sounds less startling when put into the context of a relative increase, it was certainly an area of concern for the majority female audience, particularly as this was the last session prior to the evening's social event. The symposium finished for me at this point. The unfortunate clash of the Rugby World Cup semi-final (England winning a close game, apologies to any French readers) and the Gala dinner meant I was one of the guilty non-attendees at the social event. A morning flight on the Sunday also meant I missed the final morning's lectures. Nonetheless I can conclude that this was another successful and well attended meeting with a strong underlying theme of accreditation as a focus for development over the forthcoming year.

SECOND ANNOUNCEMENT

HOPA / ISOPP 2008 Joint Annual Conference

Wednesday-Saturday, June 18-21, 2008
Anaheim Marriott, Anaheim, California

CALL FOR ABSTRACTS

HOPA's 4th Annual Conference has combined with ISOPP's 11th Annual Conference for the 2008 Joint Conference in Anaheim, California.

ABSTRACT DEADLINES

Monday, JANUARY 14, 2008:

Abstracts must describe completed research (ie, abstracts that contain results and conclusions). All accepted January abstracts will be published in an issue of the Journal of Oncology Pharmacy Practice in addition to the HOPA/ISOPP 2008 Meeting Program Book.

Trainee Abstracts ONLY

Monday, MARCH 10, 2008: Trainee (resident, fellow, student) abstracts may describe ongoing research. Only current trainees may use this deadline, although trainees are encouraged to use the January deadline if their completed research (results & conclusions) is available at that time. All accepted trainee abstracts will be published in the HOPA/ISOPP 2008 Meeting Program Book only.

ONLINE SUBMISSION PROCESS

Abstracts may be submitted starting November 1, 2007. Please go to <http://isopp.org> to submit your abstract. Questions or problems can be directed to ISOPP Research Committee Chair, Judith Smith at 001-713-500-6408 or HOPA Research Committee Chair, Kelly Markey at 001-813-745-4652.

MEETING REGISTRATION

Registration will be open some time in January. If you wish, you can e-mail info@hoparx.org with "HOPA/ISOPP 2008 Registration" in the subject line and receive an e-mail as soon as online registration becomes available.

Thank You!

HOPA/ISOPP 2008 Research Committee

Request for Peer Reviewers

For HOPA/ISOPP Abstracts

At the upcoming HOPA/ISOPP Joint Annual Conference being held June 18th -21st 2008 at the Anaheim Marriott in Anaheim, California, the HOPA Research Committee is working in collaboration with the ISOPP Research Committee to organize the research poster and platform sessions. The abstract submission deadline is January 14th 2008 for all completed research and deadline for the trainee's ongoing or completed research is March 10th 2008. We will need peer reviewers to serve for both submission deadlines with approximately two to three week turn around time. If you have time and would be interested in serving as a peer reviewer for the HOPA/ISOPP abstract submissions please contact Judith Smith at jasmith@mdanderson.org or 001-713-500-6408 or David Frame at dframe@med.umich.edu or 001-734-426-7789.

Think about nominating an ISOPP colleague for an ISOPP award - ISOPP Achievement Award or Helen McKinnon Award - see details on website

ISOPP Standards Committee Invitation

The ISOPP Standards of Practice 'Safe Handling of Cytotoxics' is now published as a supplement to the September 2007 issue of JOPP. Thanks to all the standards committee members and the three co-chairs for the amount of time and effort they contributed to make these standards a reality.

BUT

This does not mean the standards committee stops their activity, NOT AT ALL.

We have already some ideas of the direction we can go from here eg up-dating the existing standard (already ??? YES !!), creating an audit instrument to enable people to check their practice with the ISOPP standard, writing standards on areas of clinical pharmacy oncology/hematology practice, producing information on drug stability, incompatibility etc. There is still much work to be done.

Some committee members will continue on the committee, others have decided to take a break or interact with ISOPP in other ways. Maybe you would like to join the committee?

If YOU FEEL YOU CAN CONTRIBUTE to the work of the committee please contact me. Hope to hear from you soon

Johan Vandenbroucke
johan.vandenbroucke@uzgent.be

Membership fees due now - if you have not received your renewal form please contact Helen McKinnon at helenm@internet.co.nz or Helen McKinnon CMC International 52 Hall Road RD2, Hamilton 3282, New Zealand.

ISOPP Newsletter Sponsor



NIPRO
E U R O P E